Faron Pharmaceuticals Oy announces the release of new biomarker data from the ongoing Phase I/II BEXMAB study of bexmarilimab in combination with standard of care in the aggressive hematological malignancies of acute myeloid leukemia and myelodysplastic syndrome.
